Financial Data and Key Metrics Changes - The company reported record first-quarter net revenue of $210 million, a 5% increase year over year, driven by increased cannabis sales in Canada and international markets [31][36] - Net income for the quarter was $1.5 million, compared to a net loss of $34.7 million in the prior year period, indicating a significant turnaround in profitability [35][36] - Adjusted EBITDA for the quarter improved to $10.2 million from $9.3 million last year, reflecting operational efficiency [36] Business Line Data and Key Metrics Changes - Cannabis revenue increased by 5% year over year to $64.5 million, supported by a 12% growth in adult use gross revenue and a 10% growth in international cannabis [31][36] - Beverage revenue reached $55.7 million, impacted by SKU rationalization but supported by new product contributions [32][36] - Wellness revenue grew by 3% year over year to CAD 15.2 million, driven by innovations in health-focused products [32][36] Market Data and Key Metrics Changes - The Canadian cannabis business reported revenue up 4% year over year to $51 million, reinforcing its position as the largest legal cannabis company in Canada by revenue [12][36] - International cannabis revenue grew by 10% year over year to $13.4 million, despite permit challenges in Portugal [14][36] - The distribution segment's revenue increased by 9% year over year to CAD 74 million, primarily due to a stronger euro [32][36] Company Strategy and Development Direction - The company aims to leverage its global platform to drive innovation in cannabis, beverage, and wellness sectors, focusing on sustainable growth and operational efficiency [5][7] - The strategic focus includes optimizing the craft beer SKU portfolio under Project Four Twenty, which has already realized $25 million in annual savings [20][21] - The company is well-positioned to capture growth opportunities in the U.S. medical cannabis market, anticipating a potential market share of 3% to 5% in a $10 billion market [11][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the evolving regulatory landscape for cannabis, particularly in the U.S. and Europe, which could enhance patient access and market opportunities [10][11] - The company is confident in its ability to adapt to regulatory changes and is committed to continuous innovation and portfolio expansion [28][36] - Management acknowledged the challenges faced in the beverage segment but emphasized the long-term potential for growth and profitability [20][36] Other Important Information - The company reduced its outstanding debt by $7.7 million during the quarter, bringing its net debt to $3.9 million, which enhances financial flexibility for strategic opportunities [36][37] - The company has built a diversified global platform with over 40 unique brands in more than 20 countries, positioning itself as a leader in the cannabis, beverage, and wellness markets [8][9] Q&A Session Summary Question: International growth opportunities and permit delays - Management noted progress in obtaining permits in Portugal and expressed optimism about increasing production capacity in both Portugal and Germany [41][43][44] Question: Rescheduling opportunities in the U.S. - Management indicated readiness to leverage existing infrastructure and explore partnerships or acquisitions to capture opportunities in the U.S. medical cannabis market [48][51] Question: Canadian adult use market dynamics - Management highlighted a 1.3% decline in overall market pricing, with their pricing up 2% and volume growth of 6.5%, indicating strong performance relative to the market [67][70] Question: Beverage segment profitability improvement plans - Management discussed ongoing efforts in SKU rationalization and integration of acquired brands to improve margins in the beverage segment [75][78] Question: Managing risks in Portugal and Germany - Management emphasized commitment to the Portuguese market while also having contingency plans in Germany, including the ability to ship from Canada [81][84][90]

NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower. Fizzy Jane's, the sparkling seltzer line that debuted this spring in Georgia, North Carolina, and South Carolina, is now available in a 10mg HDD9 THC format, enhancing the buzz while keeping the same crisp, fruit-forward refreshment fans love ...

NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower. Fizzy Jane's, the sparkling seltzer line that debuted this spring in Georgia, North Carolina, and South Carolina, is now available in a 10mg HDD9 THC format, enhancing the buzz while keeping the same crisp, fruit-forward refreshment fans love ...

Core Insights - Tilray Brands reported its fourth-quarter results for fiscal 2025, with earnings exceeding estimates but sales falling short, both declining compared to the previous year [1][10] - Adjusted EPS was 2 cents, down 50% year over year, while revenues decreased by 2% to $224.5 million, primarily due to weak performance in cannabis and beverages [2] - The company expects adjusted EBITDA for fiscal 2026 to be between $62 million and $72 million, indicating a growth of 13-31% over the prior year [3] Financial Performance - Fiscal 2025 revenues reached $821 million, a 4% increase year over year, largely driven by non-cannabis business diversification [4] - Non-cannabis segments accounted for approximately 70% of total sales, with beverages contributing 29%, distribution 33%, and wellness 8% [5] - Beverage sales rose 19% year over year to $240.6 million, despite SKU rationalization efforts [6] Market Position and Strategy - Tilray has established a strong presence in the hemp market, holding nearly 60% branded market share in the U.S. and 80% in Canada [7] - The company is focusing on enhancing its global supply chain and cultivation footprint to meet growing demand, with expectations of benefiting from Project 420 in the second half of fiscal 2026 [8] - The cannabis segment saw a 9% decline in revenues to $249 million, with international cannabis sales growing 19%, although still a small portion of total cannabis sales [11] Competitive Landscape - Tilray faces intense competition from peers like Aurora Cannabis, Canopy Growth, and Curaleaf Holdings, all pursuing international expansion and cost optimization [12] - The company's stock has dropped 56% year to date, contrasting with a 6% growth in the industry, reflecting ongoing financial challenges and uncertainty around U.S. marijuana legalization [13] Investment Considerations - While Tilray's diversification into craft beverages and THC drinks shows strategic foresight, the decline in its core cannabis business and competitive pressures remain significant near-term challenges [15]